The $1.25 million in milestones will be paid through 101,000 shares of the 1.35 million Ligand shares held by Pfizer. * NPS Pharmaceuticals Inc., of Salt Lake City, said underwriters for its recent public offering exercised overallotment options on 450,000 shares at $15 per share, increasing net proceeds to about $48.3 million. * The Liposome Co., of Princeton, N.J., said liposomal prostaglandin E1 (TLC C-53) was designated as an orphan drug for the treatment of acute respiratory distress

206 OTHER NEWS TO NOTE * NeoPharm Inc., of Lake Forest, Ill., said it received orphan drug status from the FDA for Idoxuridinc for treatment of cancers of the soft connective tissues around bones and organs

Abelcet, which reduces adverse reactions by using a lipid-based system to deliver the anti-fungal medicine, is marketed as a second- line therapy for aspergillosis. * NeoPharm Inc., of Lake Forest, Ill., said it received orphan drug status from the FDA for Idoxuridinc for treatment of cancers of the soft connective tissues around bones and organs...Earlier this year, NeoPharm, won orphan drug status for Broxuridinc for brain tumors. * Neurobiological Technologies Inc., of Richmond, Calif., said

Abelcet, which reduces adverse reactions by using a lipid-based system to deliver the anti-fungal medicine, is marketed as a second- line therapy for aspergillosis. * NeoPharm Inc., of Lake Forest, Ill., said it received orphan drug status from the FDA for Idoxuridinc for treatment of cancers of the soft connective tissues around bones and organs...Earlier this year, NeoPharm, won orphan drug status for Broxuridinc for brain tumors. * Neurobiological Technologies Inc., of Richmond, Calif., said

GelTex, which went public in November 1995, develops non- absorbed, polymer-based drugs that selectively eliminate substances from the gastrointestinal tract. * Guilford Pharmaceuticals Inc., of Baltimore, which submitted a new drug application (NDA) in February 1996 for Gliadel, said the FDA accepted the NDA for review for brain cancer and the agency expanded the orphan drug status of Gliadel to include all forms of malignant glioma

The antiretroviral compound is a non-nucleoside reverse transcriptase inhibitor. * Celgene Corp., of Warren, N.J., said the FDA approved a fourth application for orphan drug designation of thalidomide, this one for AIDS wasting

Lexin CEO Jerry Hooks was named president, CEO and a director of Sparta. (See BioWorld Today, Jan. 22, 1996, p. 1.) * Sugen Inc., of Redwood City, Calif., said the FDA granted orphan drug status to the anticancer compound, SU101, in the treatment of ovarian cancer...Also, the FDA said NXT qualifies for orphan drug status. * Viragen Inc., of Hialeah, Fla., closed a $6 million private financing of its majority-owned subsidiary, Sector Associates Ltd., which will be renamed Viragen (Europe) Ltd

Lexin CEO Jerry Hooks was named president, CEO and a director of Sparta. (See BioWorld Today, Jan. 22, 1996, p. 1.) * Sugen Inc., of Redwood City, Calif., said the FDA granted orphan drug status to the anticancer compound, SU101, in the treatment of ovarian cancer...Also, the FDA said NXT qualifies for orphan drug status. * Viragen Inc., of Hialeah, Fla., closed a $6 million private financing of its majority-owned subsidiary, Sector Associates Ltd., which will be renamed Viragen (Europe) Ltd

The per-share price of the notes will be determined at the time of conversion. * SuperGen Inc., of Emeryville, Calif., said it received orphan drug status from the FDA for an aplastic anemia treatment, RF 1017

The company said it has expanded its Phase II through Phase IV studies business with the purchase of the Clinical Research Center, which specializes in advanced clinical development services. * SuperGen Inc., of Emeryville, Calif., said it received orphan drug status from the FDA for an aplastic anemia treatment, RF 1017

The company said it has expanded its Phase II through Phase IV studies business with the purchase of the Clinical Research Center, which specializes in advanced clinical development services. * SuperGen Inc., of Emeryville, Calif., said it received orphan drug status from the FDA for an aplastic anemia treatment, RF 1017

The company said it has expanded its Phase II through Phase IV studies business with the purchase of the Clinical Research Center, which specializes in advanced clinical development services. * SuperGen Inc., of Emeryville, Calif., said it received orphan drug status from the FDA for an aplastic anemia treatment, RF 1017

The company sold 2.85 million shares at $7 each in the IPO. * SunPharm Corp., of Jacksonville, Fla., signed a license agreement with the University of Florida Research Foundation Inc., of Gainesville, for rights to a process for making the iron chelator drug, desferrioxamine. * Synsorb Biotech Corp., of Calgary, Alberta, was granted orphan drug status from the FDA for its product, Synsorb Pk, to treat Escherichia coli infections. * Zynaxis Inc., of Malvern, Pa., and ALK A/S, of Horsholm

Elevated amounts of homocysteine cause the rare, genetic disorder, which is linked to a number of complications, such as mental retardation, skeletal abnormalities and seizure disorders. * RiboGene Inc., of Hayward, Calif., was awarded a small business innovation research Phase II grant up to $750,000 to develop drugs for fungal infections. * Synsorb Biotech Corp., of Calgary, Alberta, was granted orphan drug status from the FDA for its product, Synsorb Pk, to treat Escherichia coli infections

About 1 million of the shares were offered by the company. * RGene Therapeutics Inc., of The Woodlands, Texas, said its gene therapeutic RGG0853 for advanced ovarian cancer was granted orphan drug designation. * Receptagen Ltd., of Edmonds, Wash., entered into an option agreement to purchase an unnamed privately held supplier of drugs and specialty chemicals, oils and botanicals

Sugen Inc., of Redwood City, Calif., received orphan drug status from the FDA for the company's lead anticancer drug candidate, SU101, for treatment of malignant glioma, which is a brain tumor

Sugen Inc., of Redwood City, Calif., received orphan drug status from the FDA for the company's lead anticancer drug candidate, SU101, for treatment of malignant glioma, which is a brain tumor

GenVec Inc., of Rockville, Md., said its gene therapy vector under development for treatment of cystic fibrosis was granted orphan drug status by the FDA

Other News To Note Centocor Inc., of Malvern, Pa., said ReoPro, an anti-platelet drug, has been cleared for marketing in Germany and France for high-risk angioplasty patients